Dashboard/INCY/JAKAFI/event

ReadoutTopline Readout

JAKAFI + Parsaclisib TRANSFORM-2 Phase 3 Readout

INCY·JAKAFI·Myelofibrosis·

Approved

·NCT04173494

current best date

'26

HALF4 months

Takeaway

Phase 3 readout for parsaclisib added on top of JAKAFI in myelofibrosis patients with sub-optimal response to ruxolitinib monotherapy. Watch: spleen volume reduction (SVR35) and total symptom score (TSS50) at week 24 vs. JAKAFI + placebo.

What’s at stake

market · comparables · base rate · prior moves

Market opportunity

—

company filings

Peer comparables

1 readout

ClinicalTrials.gov

Stage base rate

~100%

BIO Industry Analysis 2023 (2011–2020)

Avg prior-readout move

—

historical price reactions

MoAJAK1/JAK2 inhibitor

JAKAFI (ruxolitinib) is an oral small-molecule inhibitor developed by Incyte that blocks Janus kinase 1 and 2 (JAK1/JAK2), enzymes whose overactivity drives abnormal blood cell proliferation and inflammatory signaling in myeloproliferative diseases. The drug is approved for myelofibrosis, polycythemia vera, and steroid-refractory graft-versus-host disease; in myelofibrosis, JAK inhibition reduces the enlarged spleen and debilitating constitutional symptoms caused by progressive marrow fibrosis. Incyte is studying ruxolitinib combined with the PI3Kδ inhibitor parsaclisib in patients who have an inadequate response to JAKAFI monotherapy.

Indication

Oncology - Heme

Myelofibrosis

MeSH · D009190

No primer in glossary yet.

Trial

active

NCT04173494 ↗

TRANSFORM-2 Phase 3 Ruxolitinib + Parsaclisib

Reference data · comparable readouts

How Appr readouts in Oncology - Heme have landed.

Reference, not prediction. We surface the historical record so you can read it yourself. We never extrapolate to the upcoming event.

Positive

0/0

0% in record

Primary endpoint hit

across 0 readouts

Drug · sponsorPhase · yearOutcomeKey metricSource

pirtobrutinib (BRUIN-321)

LLY · CLL

Ph3 · Dec 2024positivePFS HR 0.54PR

mosunetuzumab

RHHBY · r/r FL

Ph2 · Jun 2022positiveCR rate 60%conference

sorted by phase match, then recency · sources span PR wires, CT.gov, FDA notices, and conference presentations · we never editorialize the outcome label

Competitive landscape

4 peers in Oncology - Heme · ranked by indication + modality match

Drug	Company	Modality	Mechanism	Next catalyst
CASGEVYexagamglogene autotemcel	CRSP	cell therapy	CRISPR/Cas9 BCL11A enhancer edit	CONFERENCE · Dec 26
reni-cel	EDIT	cell therapy	CRISPR/Cas12a HBG1/2 promoter edit	CONFERENCE · May 26
BEAM-101	BEAM	cell therapy	base editing of HBG1/2 to reactivate fetal hemoglobin	READOUT · Dec 26
CB-010	CRBU	cell therapy	allogeneic CRISPR-edited anti-CD19 CAR-T	CONFERENCE · May 26

Disclosure trail

1 observation · sorted by confidence

Mar 18, 2026·1mo agopinned · highest confidence
HIGH confPR
top claim
H2'26
HALF
“TRANSFORM-2, evaluating add-on parsaclisib in patients with myelofibrosis with sub-optimal response to ruxolitinib, is expected to read out in the second half of 2026.”
conf 85%via llm

MethodologyEvery catalyst date is anchored to a primary source. Disclosures with confidence ≥ 0.85 auto-publish; the rest are reviewed by a human within 24 hours. We never interpret data — we organize public information.